KEGG   DRUG: Imipenem, cilastatin and relebactam
Entry
D11621            Mixture   Drug                                   
Name
Imipenem, cilastatin and relebactam;
Relebactam hydrate, imipenem hydrate and cilastatin sodium;
Recarbrio (TN)
Product
RECARBRIO (Merck Sharp & Dohme LLC)
Component
Imipenem [DR:D00206], Cilastatin sodium [DR:D02194], Relebactam [DR:D10726]
Remark
Therapeutic category: 6129
ATC code: J01DH56
Product: D11621<JP/US>
Efficacy
Antibacterial
  Disease
Uncomplicated urinary tract infection [DS:H01176]
Target
penicillin binding protein
beta-lactamases
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J01 ANTIBACTERIALS FOR SYSTEMIC USE
   J01D OTHER BETA-LACTAM ANTIBACTERIALS
    J01DH Carbapenems
     J01DH56 Imipenem, cilastatin and relebactam
      D11621  Imipenem, cilastatin and relebactam <JP/US>
USP drug classification [BR:br08302]
 Antibacterials
  Carbapenems
   Cilastatin/ Imipenem/ Relebactam
    D11621  Imipenem, cilastatin and relebactam
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  61  Antibiotics
   612  Acting mainly on gram-negative bacteria
    6129  Others
     D11621  Imipenem, cilastatin and relebactam
Antimicrobials [BR:br08307]
 Antibacterials
  Cell wall biosynthesis inhibitor, beta-lactam
   Carbapenem
    D11621  Imipenem, cilastatin and relebactam <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11621
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11621
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11621
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11621
Other DBs
PubChem: 405226488
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system